Abstract Library

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#1936 The Expression of IGF Signaling Pathway Genes Is Frequently Elevated in Pancreatic Neuroendocrine Tumors, but Is Downregulated in Metastases

Introduction: Studies have implicated EGFR, IGF and mTOR signaling pathways in the regulation of pNET growth. Interpretation of these studies is complex due to tumor subtype heterogeneity and differences in molecular analysis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Speel E

Authors: Henfling M, Versleijen-Jonkers Y, Starke A, Riedl R, Sprij-Mooij D,

Keywords: , ,

#319 Expression of EGFR and IGF Pathway Genes in Insulinomas

Introduction: Anti-epidermal growth factor receptor (EGFR) therapy has been suggested in patients with inoperable/progressive endocrine pancreatic tumors (EPTs). However, various % EGFR-expressing EPTs are reported.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Henfling M, Jonkers Y, Claessen S, Ramaekers F, Starke A,

Keywords: endocrine pancreatic tumors, insulinomas, EGFR, IGF2, IGF targeting therapy ,